News GSK Partnership Featured in Fierce Pharma and BioSpace Writer : Alteogen Date : 2026.01.21 https://www.fiercepharma.com/pharma/gsk-offers-alteogen-285m-subq-jemperli-licensing-pact?utm_medium=email&utm_source=nl&utm_campaign=LS-NL-FiercePharma&oly_enc_id=4390I9280056E4Ihttps://www.biospace.com/deals/gsk-joins-growing-pd-1-subq-push-with-alteogen-alliance-worth-up-to-285m?utm_campaign=Newsletter%20%7C%20GenePool&utm_medium=email&_hsenc=p2ANqtz-9SssRxcjfW3IYGfMIy-uxN9UVO3H4qfzbJK1lwcqRwZwWpzDgfj6yhiEy4_5_f8egiIVcJlgePNAROjHU4_RG2MYE7Gg&_hsmi=399687593&utm_content=399687593&utm_source=hs_email PREV Alteogen Announces Exclusive License Agreement with Tesaro, a Subsidiary of GSK, for the Development of a Subcutaneous Formulation of Dostarlimab Enabled by Hybrozyme™ Technology NEXT There's no next post. List
